CorMedix Inc. has entered into a definitive agreement to acquire Melinta Therapeutics, LLC, a significant strategic move that will create a new, diversified specialty pharmaceutical company. The acquisition is valued at $300 million in upfront consideration, with a breakdown of $260 million in cash and $40 million in CorMedix equity issued to Melinta shareholders as pre-funded warrants. The deal also includes potential future payments, such as a $25 million regulatory milestone for a new indication of REZZAYO®, along with tiered royalties on its U.S. net sales. The acquisition is a testament to the remarkable transformation Melinta has undergone since 2020, achieving 85% revenue growth, positive cash flow, and sustainable profitability while becoming a leader in acute care.

This merger will strategically expand CorMedix's commercial portfolio to include seven marketed products, including the flagship anti-infective REZZAYO®, along with MINOCIN®, VABOMERE®, KIMYRSA®, ORBACTIV®, and BAXDELA®, in addition to the cardiovascular product TOPROL-XL®. The acquisition leverages Melinta’s established commercialization platform and experienced team, positioning the combined company to become a leader in the specialty pharmaceutical business. The boards of both companies have approved the acquisition, which is expected to close in September, pending customary regulatory and antitrust approvals.